MCID: ADN027
MIFTS: 61

Adenomyosis

Categories: Muscle diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Adenomyosis

MalaCards integrated aliases for Adenomyosis:

Name: Adenomyosis 58 12 77 54 45 15 17
Endometriosis of Uterus 12 15 74
Endometriosis of Myometrium 12
Endometriosis, Myometrium 12
Endometriosis Interna 12
Uterine Adenomyosis 12

Characteristics:

OMIM:

58
Inheritance:
autosomal vs. x-linked dominant



Classifications:



External Ids:

Disease Ontology 12 DOID:288
OMIM 58 600458
ICD9CM 36 617.0
MeSH 45 D062788
NCIt 51 C6996
SNOMED-CT 69 76376003
ICD10 34 N80.0
MedGen 43 C0341858
UMLS 74 C0341858

Summaries for Adenomyosis

NIH Rare Diseases : 54 Adenomyosis is a condition that affects the uterus. In women with adenomyosis, the endometrial tissue (which typically lines the uterus) moves into the outer, muscular walls of the uterus. Some women may have no signs or symptoms of the condition. When present, features of the condition include heavy menstrual bleeding, painful menstrual periods, and pelvic pain during intercourse. Some women may also develop an adenomyoma, which is a mass or growth within the uterus. The underlying cause of the condition is currently unknown. In general, treatment is based on the signs and symptoms present in each person. Forms of birth control that contain progesterone (such as birth control pills or an IUD) may decrease heavy bleeding while certain medications can be used to manage pain. In severe cases, a hysterectomy may be recommended.

MalaCards based summary : Adenomyosis, also known as endometriosis of uterus, is related to uterine anomalies and endometrial adenocarcinoma. An important gene associated with Adenomyosis is PGR (Progesterone Receptor), and among its related pathways/superpathways are GPCR Pathway and Nanog in Mammalian ESC Pluripotency. The drugs Estradiol and Polyestradiol phosphate have been mentioned in the context of this disorder. Affiliated tissues include uterus, breast and pituitary, and related phenotypes are abnormal bleeding and dysmenorrhea

Disease Ontology : 12 A uterine disease that is characterized by the presence of endometrial tissue grows outside of the endometrium, such as into the myometrium.

OMIM : 58 Adenomyosis is characterized by the presence of endometrial glands and stroma within the myometrium. Abnormal uterine bleeding and dysmenorrhea are the most characteristic symptoms, occurring in approximately 65% of cases (Arnold et al., 1995). (600458)

Wikipedia : 77 Adenomyosis is a gynecologic medical condition characterized by the abnormal presence of endometrial... more...

Related Diseases for Adenomyosis

Diseases related to Adenomyosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 220)
# Related Disease Score Top Affiliating Genes
1 uterine anomalies 31.5 CDH1 CYP19A1 ESR1 PGR VEGFA
2 endometrial adenocarcinoma 30.6 ESR1 HOXA10 PGR VEGFA
3 endometriosis 30.3 CYP19A1 ESR1 GNRH1 HOXA10 PGR PTGS2
4 adenosarcoma 30.2 ESR1 MME PGR
5 myoma 30.1 CYP19A1 ESR1 GNRH1 HOXA10 PGR
6 endometriosis of ovary 30.0 CYP19A1 ESR1 HOXA10 PGR
7 leiomyoma 30.0 CYP19A1 ESR1 GNRH1 MME PGR
8 endometrial stromal sarcoma 29.9 CYP19A1 ESR1 MME PGR
9 leiomyomatosis 29.9 ESR1 GNRH1 PGR
10 intravenous leiomyomatosis 29.9 ESR1 MME
11 breast fibroadenoma 29.4 CYP19A1 ESR1 MME PGR
12 endometrial cancer 28.2 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MME
13 breast cancer 28.0 CDH1 CYP19A1 ESR1 GNRH1 MMP2 MMP9
14 adenocarcinoma 10.6
15 parotitis 10.5 MMP2 MMP9
16 light chain deposition disease 10.5 MMP2 MMP9
17 female reproductive endometrioid cancer 10.5 ESR1 PGR
18 intramuscular hemangioma 10.5 ESR1 PGR
19 glycogen-rich clear cell breast carcinoma 10.5 ESR1 PGR
20 vestibular gland benign neoplasm 10.5 ESR1 PGR
21 bartholin's gland adenoma 10.5 ESR1 PGR
22 vulvar syringoma 10.5 ESR1 PGR
23 lung leiomyoma 10.5 ESR1 PGR
24 extracranial arteriovenous malformation 10.5 MMP2 MMP9
25 glassy cell carcinoma of the cervix 10.4 ESR1 PGR
26 focal myositis 10.4 MMP2 MMP9
27 vulvar benign neoplasm 10.4 ESR1 PGR
28 trigonitis 10.4 ESR1 PGR
29 vulvar leiomyoma 10.4 ESR1 PGR
30 villous adenocarcinoma 10.4 MMP2 MMP9
31 balanitis xerotica obliterans 10.4 PTGS2 VEGFA
32 spastic entropion 10.4 MMP2 MMP9
33 infertility 10.4
34 lentigo maligna melanoma 10.4 MMP2 MMP9
35 predominantly cortical thymoma 10.4 ESR1 PGR
36 breast medullary carcinoma 10.4 ESR1 PGR
37 angiokeratoma circumscriptum 10.4 MMP9 VEGFA
38 breast scirrhous carcinoma 10.4 ESR1 PGR
39 bartholin's gland benign neoplasm 10.4 ESR1 PGR
40 oncocytic breast carcinoma 10.4 ESR1 PGR
41 intracystic papillary adenoma 10.4 PGR PRL
42 acute transverse myelitis 10.4 MMP2 MMP9
43 senile ectropion 10.4 MMP2 MMP9
44 progesterone resistance 10.4 ESR1 PGR
45 endometrial squamous cell carcinoma 10.4 ESR1 PGR
46 cribriform carcinoma 10.4 ESR1 PGR
47 gingival hypertrophy 10.4 MMP9 TIMP2
48 endometrial mucinous adenocarcinoma 10.4 ESR1 PGR
49 adenoid basal cell carcinoma 10.4 ESR1 PGR
50 ischemic colitis 10.3 MMP2 MMP9 VEGFA

Graphical network of the top 20 diseases related to Adenomyosis:



Diseases related to Adenomyosis

Symptoms & Phenotypes for Adenomyosis

Human phenotypes related to Adenomyosis:

33
# Description HPO Frequency HPO Source Accession
1 abnormal bleeding 33 HP:0001892
2 dysmenorrhea 33 HP:0100607
3 abnormality of the genitourinary system 33 HP:0000119

Symptoms via clinical synopsis from OMIM:

58
Lab:
dysmenorrhea
endometrial glands and stroma within the myometrium
abnormal uterine bleeding

G U:
adenomyosis

Clinical features from OMIM:

600458

MGI Mouse Phenotypes related to Adenomyosis:

47 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 CDH1 CYP19A1 ESR1 GNRH1 MME MMP2
2 behavior/neurological MP:0005386 10.27 CYP19A1 ESR1 MMP9 NGF OXTR PGR
3 cardiovascular system MP:0005385 10.26 CDH1 CYP19A1 ESR1 MMP2 MMP9 NGF
4 growth/size/body region MP:0005378 10.26 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP2
5 immune system MP:0005387 10.26 CDH1 CYP19A1 ESR1 GNRH1 MME MMP2
6 endocrine/exocrine gland MP:0005379 10.24 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 OXTR
7 integument MP:0010771 10.23 CDH1 CYP19A1 ESR1 GNRH1 MME MMP9
8 hematopoietic system MP:0005397 10.16 CYP19A1 ESR1 GNRH1 MMP2 MMP9 PGR
9 digestive/alimentary MP:0005381 10.15 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP9
10 nervous system MP:0003631 10.1 CYP19A1 ESR1 GNRH1 HOXA10 MMP2 MMP9
11 muscle MP:0005369 10.06 CYP19A1 ESR1 MMP2 MMP9 NGF OXTR
12 neoplasm MP:0002006 10.02 CDH1 ESR1 GNRH1 MMP2 MMP9 PGR
13 liver/biliary system MP:0005370 9.98 CYP19A1 ESR1 GNRH1 MME PRL PTGS2
14 normal MP:0002873 9.9 CDH1 CYP19A1 ESR1 GNRH1 MMP2 NGF
15 no phenotypic analysis MP:0003012 9.8 CDH1 ESR1 NGF OXTR PGR PTGS2
16 reproductive system MP:0005389 9.7 CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP9
17 skeleton MP:0005390 9.28 CYP19A1 ESR1 GNRH1 HOXA10 MMP2 MMP9

Drugs & Therapeutics for Adenomyosis

Drugs for Adenomyosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Early Phase 1,Not Applicable 50-28-2 5757
2
Polyestradiol phosphate Approved Phase 4,Phase 3,Early Phase 1,Not Applicable 28014-46-2
3
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Ibuprofen Approved Phase 4 15687-27-1 3672
6
Dienogest Approved Phase 4,Not Applicable 65928-58-7
7
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3 57-83-0 5994
8
Nandrolone decanoate Approved, Illicit Phase 4,Not Applicable 360-70-3 9677
9
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4,Not Applicable 62-90-8 229455
10
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
11
Norethindrone Approved Phase 4 68-22-4 6230
12
Buserelin Approved, Investigational Phase 4 57982-77-1
13
Nandrolone Experimental, Investigational Phase 4,Not Applicable 434-22-0 9904
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 Estradiol 3-benzoate Phase 4,Phase 3,Early Phase 1,Not Applicable
16 Estrogens Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable
17 Estradiol 17 beta-cypionate Phase 4,Phase 3,Early Phase 1,Not Applicable
18 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
20 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
21 Contraceptives, Oral, Combined Phase 4,Phase 2,Early Phase 1,Not Applicable
22 Contraceptive Agents Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable
23 Contraceptives, Oral Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable
24 Ulipristal acetate Phase 4,Phase 2 126784-99-4
25 Anti-Inflammatory Agents Phase 4,Not Applicable
26 Cyclooxygenase Inhibitors Phase 4
27 Analgesics Phase 4,Phase 3
28 Analgesics, Non-Narcotic Phase 4
29 Anti-Inflammatory Agents, Non-Steroidal Phase 4
30 Antirheumatic Agents Phase 4
31 Antipyretics Phase 4
32 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
33 Contraceptive Agents, Male Phase 4,Not Applicable
34 Anabolic Agents Phase 4,Not Applicable
35 Androgens Phase 4,Not Applicable
36 Oxytocics Phase 4
37 Triptorelin Pamoate Phase 4,Phase 3
38 Norethindrone Acetate Phase 4
39
Goserelin Approved Phase 2, Phase 3 65807-02-5 5311128 47725
40
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
41
Mifepristone Approved, Investigational Phase 2, Phase 3 84371-65-3 55245
42 Ramosetron Investigational Phase 3 132036-88-5
43
Lactitol Investigational Phase 2, Phase 3 585-88-6, 585-86-4 493591
44 Deslorelin Investigational, Vet_approved Phase 3,Not Applicable 57773-65-6
45 Trace Elements Phase 3
46 Micronutrients Phase 3
47 Nutrients Phase 3
48 Antiemetics Phase 3,Not Applicable
49 Serotonin Antagonists Phase 3
50 Neurotransmitter Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
2 Oxytocin in MRI-HIFU Enrolling by invitation NCT03937401 Phase 4 Oxytocin
3 Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. Not yet recruiting NCT03946722 Phase 4 GnRH analogue downregulation
4 Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Not yet recruiting NCT03654144 Phase 4 Dienogest;Combined Oral Contraceptive
5 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
6 Efficacy of Trace Elements in the Treatment of Endometriosis: a Pilot Study Unknown status NCT02437175 Phase 3
7 Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy Unknown status NCT01483417 Phase 3
8 The Use of Doppler to Diagnose Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
9 Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01048931 Phase 3
10 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
11 Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis Completed NCT01218581 Phase 2, Phase 3 received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
12 Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
13 Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Recruiting NCT03520439 Phase 2, Phase 3 Mifepristone;Placebo
14 Elastic Abdominal Binder After Open Abdominal Surgery for Benign Gynecologic Conditions Recruiting NCT03820115 Phase 3
15 Impact of Ultra-long Versus Long Down-regulation Protocol on IVF/ICSI in Adenomyosis Not yet recruiting NCT03940807 Phase 3 11.25mg GnRH agonist;0.1 mg GnRH agonist;25 µg transdermal oestradiol
16 Adenomyosis and Ulipristal Acetate Unknown status NCT02587000 Phase 2 Ulipristal acetate;Placebo
17 LNG-IUS for Treatment of Dysmenorrhea Completed NCT01601366 Phase 2 Combined oral contraceptives
18 Tactile Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding Completed NCT02248194 Phase 2
19 Superior Hypogastric Nerve Block for Pain Control Post-UFE Completed NCT02270255 Phase 2 0.75% Ropivacaine;1% Xylocaine
20 Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis Not yet recruiting NCT03749109 Phase 2 Quinagolide 1080 µg;Placebo
21 Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis Withdrawn NCT02794467 Phase 2 Epelsiban;Placebo
22 Vaginal Bromocriptine for Treatment of Adenomyosis Completed NCT01821001 Phase 1 Vaginal Bromocriptine
23 Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Unknown status NCT03037944 Early Phase 1 Yasmin
24 Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis Unknown status NCT01259180 Not Applicable
25 Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis Unknown status NCT00172588
26 Proliferation of Endometrial Stromal Cells in Adenomyosis Unknown status NCT00173212
27 Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Unknown status NCT02556411 Not Applicable LNG-IUS 13,5 mg Levonorgestrel;Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
28 Health-Related QoL Among Women Receiving Hysterectomy in NTUH Unknown status NCT00155870
29 Progestin Treatment for Endometrial Stromal Cells in Adenomyosis Unknown status NCT00155051
30 To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01564602 Not Applicable
31 Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Unknown status NCT02086344 Not Applicable
32 Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis Unknown status NCT03006406 Not Applicable Long term GnRH-a (3.75mg)
33 The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone (AMH) Unknown status NCT00928044
34 Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy Unknown status NCT01289314 Not Applicable
35 Histopathological Diagnosis of Adenomyosis Completed NCT02340533 Not Applicable
36 Norwegian Adenomyosis Study I Completed NCT02201719
37 Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis Completed NCT03027648 Not Applicable
38 Levonorgestrel Intrauterine System and Adenomyosis Completed NCT03104309 Not Applicable
39 Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis Completed NCT03778359 Leuprorelin;Dienogest;Progestins
40 New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma Completed NCT02997787
41 What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Completed NCT01992718 Early Phase 1
42 Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis Completed NCT03586063
43 Use of Dexamethasone in Uterine Artery Embolization Completed NCT02056717 Not Applicable Dexamethasone;Normal saline
44 Uterine Artery Embolization for Symptomatic Fibroids Completed NCT00354471
45 Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Completed NCT02192606 Not Applicable
46 Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy Completed NCT01806012 Not Applicable
47 AMH Levels Change During Treatment With GnRh Agonist Completed NCT02086279 Not Applicable GnRH analogue
48 Magnetic Resonance Imaging (MRI) Hysterosalpingography Versus Radiographic Hysterosalpingography in Female Infertility Completed NCT02108665 Not Applicable
49 Surgical Success After Laparoscopic vs Abdominal Hysterectomy Completed NCT01793584 Not Applicable
50 Electronic Catheter Stethoscope Completed NCT01463462

Search NIH Clinical Center for Adenomyosis

Cochrane evidence based reviews: adenomyosis

Genetic Tests for Adenomyosis

Anatomical Context for Adenomyosis

MalaCards organs/tissues related to Adenomyosis:

42
Uterus, Breast, Pituitary, Ovary, Testes, Endothelial, Cervix

Publications for Adenomyosis

Articles related to Adenomyosis:

(show top 50) (show all 1202)
# Title Authors Year
1
Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids. ( 30382803 )
2019
2
Correlation of LOX‑5 and COX‑2 expression with inflammatory pathology and clinical features of adenomyosis. ( 30387822 )
2019
3
Does presence of adenomyosis affect reproductive outcome in IVF cycles? A retrospective analysis of 973 patients. ( 30446308 )
2019
4
Histological evaluation of the prevalence of adenomyosis, myomas and of their concomitance. ( 30486633 )
2019
5
The Disease Phenotype of Adenomyosis-Affected Women Correlates With Specific Serum Cytokine Profiles. ( 30518300 )
2019
6
Malignant transformation of adenomyosis: literature review and meta-analysis. ( 30519753 )
2019
7
Transmembrane G protein-coupled receptor 30 gene polymorphisms and uterine adenomyosis in Korean women. ( 30626229 )
2019
8
Adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas and/or adenomyosis. ( 30675965 )
2019
9
What if deep endometriotic nodules and uterine adenomyosis were actually two forms of the same disease? ( 30722943 )
2019
10
In Vivo Adenomyosis Tissue Sampling Using a Transvaginal Ultrasound-guided Core Biopsy Technique for Research Purposes: Safety, Feasibility, and Effectiveness. ( 30738919 )
2019
11
Diffuse massive adenomyosis and infertility. Is it possible to treat this condition? ( 30753160 )
2019
12
Two- and three-dimensional transvaginal ultrasonography for diagnosis of adenomyosis of the inner myometrium. ( 30792048 )
2019
13
Decreased Expression of Cannabinoid Receptors in the Eutopic and Ectopic Endometrium of Patients with Adenomyosis. ( 30800671 )
2019
14
Systematic review and meta-analysis of adverse pregnancy outcomes after uterine adenomyosis. ( 30828808 )
2019
15
Expression of Cannabinoid Receptors in Myometrium and its Correlation With Dysmenorrhea in Adenomyosis. ( 30832539 )
2019
16
Intrauterine cystic adenomyosis: Report of two cases. ( 30863769 )
2019
17
Adenomyosis: genetics of estrogen metabolism. ( 30878995 )
2019
18
Clinical efficacy of adenomyomectomy using "H" type incision combined with Mirena in the treatment of adenomyosis. ( 30882624 )
2019
19
Erratum: The rate of euploid miscarriage is increased in the setting of adenomyosis. ( 30895972 )
2019
20
Recent advances in understanding and managing adenomyosis. ( 30918629 )
2019
21
Adenomyosis:A Clinico-pathological Study. ( 30924123 )
2019
22
Uterine polyps, adenomyosis, leiomyomas, and endometrial receptivity. ( 30929720 )
2019
23
Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis. ( 30994010 )
2019
24
Association between preoperative adenomyosis detection rate during pelvic ultrasonography and the specialty of the reading physician. ( 31004795 )
2019
25
Vaginal Bromocriptine Improves Pain, Menstrual Bleeding and Quality of Life in Women with Adenomyosis; A Pilot study. ( 31025313 )
2019
26
Management of uterine adenomyosis: current trends and uterine artery embolization as a potential alternative to hysterectomy. ( 31030317 )
2019
27
Impact of Coexisting Uterine Adenomyosis on the Survival Outcome of Patients with Endometrial Cancer: A Retrospective Cohort Study ( 31030493 )
2019
28
Uterine artery embolisation in women with symptomatic adenomyosis. ( 31036387 )
2019
29
Incidental Detection of Endometriosis with 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in a Patient with Cervical Intraepithelial Neoplasia and Adenomyosis. ( 31040534 )
2019
30
Elasticity of adenomyosis is increased after GnRHa therapy and is associated with spontaneous pregnancy in infertile patents. ( 31067498 )
2019
31
Effect of pretreatment with a levonorgestrel-releasing intrauterine system on IVF and vitrified-warmed embryo transfer outcomes in women with adenomyosis. ( 31109894 )
2019
32
Sonographic classification and reporting system for diagnosing adenomyosis. ( 29790217 )
2019
33
The Possible Role of Eukaryotic Translation Initiation Factor 3 Subunit e (eIF3e) in the Epithelial-Mesenchymal Transition in Adenomyosis. ( 29871559 )
2019
34
Menstruation-related disseminated intravascular coagulation in an adenomyosis patient: case report and review of the literature. ( 30044152 )
2019
35
Inter-rater agreement in the diagnosis of adenomyosis by 2- and 3-dimensional transvaginal ultrasonography. ( 30182497 )
2019
36
Effects of adenomyosis on obstetric outcomes. ( 30318871 )
2019
37
Risk of preterm birth, low birthweight and small-for-gestational-age infants in pregnancies with adenomyosis: A cohort study of the Japan Environment and Children's Study. ( 30367455 )
2019
38
Coexistence of adenomyosis, adenocarcinoma, endometrial and myometrial lesions in resected uterine specimens. ( 30101029 )
2018
39
Uterine adenomyosis and adenomyoma: the surgical approach. ( 29566853 )
2018
40
RhoA/ROCK/ARHGAP26 signaling in the eutopic and ectopic endometrium is involved in clinical characteristics of adenomyosis. ( 30387365 )
2018
41
Elusive adenomyosis: a plea for an international classification system to allow artificial intelligence approaches to reset our clinical management. ( 30396546 )
2018
42
A sonographic classification of adenomyosis: interobserver reproducibility in the evaluation of type and degree of the myometrial involvement. ( 30396560 )
2018
43
P21-Activated Kinase 1 Overactivates in Eutopic Endometrium of Adenomyosis. ( 30453819 )
2018
44
Catechol-O-methyltransferase 158G/A polymorphism and endometriosis/adenomyosis susceptibility: A meta-analysis in the Chinese population. ( 30539833 )
2018
45
Cerebral infarcts associated with adenomyosis: a rare risk factor for stroke in middle-aged women: a case series. ( 30567506 )
2018
46
Decreased Endometrial IL-10 Impairs Endometrial Receptivity by Downregulating HOXA10 Expression in Women with Adenomyosis. ( 30687738 )
2018
47
Window of Implantation is Significantly Displaced in Patients with Adenomyosis with Previous Implantation Failure as Determined by Endometrial Receptivity Assay. ( 30787520 )
2018
48
Biological differences between focal and diffuse adenomyosis and response to hormonal treatment. ( 30850322 )
2018
49
The rate of euploid miscarriage is increased in the setting of adenomyosis. ( 30895252 )
2018
50
Cerebral Infarcts by Nonbacterial Thrombotic Endocarditis Associated with Adenomyosis: A Case Report. ( 29108806 )
2018

Variations for Adenomyosis

Expression for Adenomyosis

Search GEO for disease gene expression data for Adenomyosis.

Pathways for Adenomyosis

Pathways related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.56 ESR1 GNRH1 MMP2 MMP9 NGF PTGS2
2
Show member pathways
13.13 CDH1 ESR1 GNRH1 NGF TIMP2 VEGFA
3
Show member pathways
12.91 EIF3E GNRH1 NGF PTGS2 TIMP2
4
Show member pathways
12.89 ESR1 MMP2 MMP9 PGR VEGFA
5 12.61 CDH1 ESR1 MMP2 MMP9 PTGS2 VEGFA
6
Show member pathways
12.56 CDH1 ESR1 MMP2 MMP9 VEGFA
7 12.14 ESR1 MMP2 MMP9 VEGFA
8 11.98 CDH1 CYP19A1 ESR1 VEGFA
9
Show member pathways
11.93 CDH1 GNRH1 NGF TIMP2
10 11.88 CDH1 MMP2 MMP9
11
Show member pathways
11.81 ESR1 PGR PRL
12 11.81 MMP2 MMP9 PTGS2 VEGFA
13
Show member pathways
11.76 MMP2 MMP9 TIMP2
14 11.65 CDH1 MMP2 MMP9
15 11.52 MMP2 MMP9 TIMP2
16 11.51 MMP2 MMP9 PTGS2 TIMP2
17 11.49 MMP9 PTGS2 VEGFA
18 11.38 ESR1 PTGS2 VEGFA
19 11.32 CDH1 MMP2 MMP9 VEGFA
20 11.24 CDH1 MMP2 MMP9 PTGS2 VEGFA
21 11.16 MME MMP2 MMP9
22
Show member pathways
11.06 MMP2 MMP9 PTGS2 VEGFA
23 11.02 ESR1 MMP2 MMP9
24 10.92 MMP9 TIMP2 VEGFA
25 10.86 MME MMP2 MMP9
26 10.11 CYP19A1 ESR1

GO Terms for Adenomyosis

Cellular components related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 GNRH1 MMP2 MMP9 NGF PRL TIMP2
2 extracellular region GO:0005576 9.56 CDH1 GNRH1 MMP2 MMP9 NGF PRL
3 extracellular matrix GO:0031012 8.92 MMP2 MMP9 TIMP2 VEGFA

Biological processes related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.92 GNRH1 MMP9 NGF PTGS2 VEGFA
2 cytokine-mediated signaling pathway GO:0019221 9.84 MMP2 MMP9 PTGS2 VEGFA
3 female pregnancy GO:0007565 9.73 GNRH1 OXTR PRL
4 response to organic substance GO:0010033 9.72 CDH1 PTGS2 TIMP2
5 memory GO:0007613 9.67 NGF OXTR PTGS2
6 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.65 NGF PTGS2 VEGFA
7 extracellular matrix disassembly GO:0022617 9.63 MMP2 MMP9 TIMP2
8 response to cytokine GO:0034097 9.61 OXTR PTGS2 TIMP2
9 androgen metabolic process GO:0008209 9.59 CYP19A1 ESR1
10 macrophage differentiation GO:0030225 9.58 MMP9 VEGFA
11 mammary gland alveolus development GO:0060749 9.58 ESR1 VEGFA
12 lactation GO:0007595 9.58 OXTR PRL VEGFA
13 estrous cycle GO:0044849 9.57 GNRH1 OXTR
14 embryo implantation GO:0007566 9.54 MMP2 MMP9 PTGS2
15 mammary gland development GO:0030879 9.5 CYP19A1 PGR PRL
16 response to drug GO:0042493 9.46 CDH1 OXTR PTGS2 TIMP2
17 response to organic cyclic compound GO:0014070 9.43 GNRH1 OXTR PTGS2
18 ovulation cycle GO:0042698 9.21 GNRH1
19 response to estradiol GO:0032355 9.13 ESR1 OXTR PTGS2
20 uterus development GO:0060065 8.8 CYP19A1 ESR1 HOXA10

Molecular functions related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metalloendopeptidase inhibitor activity GO:0008191 9.16 NGF TIMP2
2 metalloendopeptidase activity GO:0004222 9.13 MME MMP2 MMP9
3 zinc ion binding GO:0008270 9.1 ESR1 MME MMP2 MMP9 PGR TIMP2

Sources for Adenomyosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....